정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1367 | Recruiting | First in Human Study of ChAdOx1-HBV | Healthy | Biological: ChAdOx1-HBV | Phase 1 | Vaccitech (UK) Limited | INDUSTRY | 52 | All | 18 Years ~ 65 Years | University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom Oxford University Hospitals Nhs Foundation Trust, Oxford, Oxfordshire, United Kingdom Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Headington, Oxford, United Kingdom Medicines Evaluations Unit, Manchester, United Kingdom |
| 1366 | Active, not recruiting | First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults | Seasonal Influenza | Biological: VRC-FLUMOS0111-00-VP (FluMos-v1) Biological: Flucelvax |
Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) | NIH | 40 | All | 18 Years ~ 50 Years | National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
| 1365 | Recruiting | First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects | SARS-CoV-2 (COVID-19) | Drug: Orally Suspension of CoV2-OGEN1 | Phase 1 | Syneos Health, US Specialty Formulations, LLC | OTHER | 45 | All | 18 Years ~ 56 Years | Auckland Clinical Studies Ltd (NZCR OpCo Limited), Grafton, Auckland, New Zealand |
| 1364 | Completed | First-in-Human Study of Orally Administered GS-441524 for COVID-19 | COVID-19 | Drug: GS-441524 | Phase 1 | Copycat Sciences LLC | INDUSTRY | 1 | Female | 18 Years | Copycat Sciences Study Site, Houston, Texas, United States |
| 1363 | Completed | First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19. | Viral Disease | Drug: PF-07304814 Drug: Placebo |
Phase 1 | Pfizer | INDUSTRY | 26 | All | 18 Years ~ 79 Years | El Camino Health, Mountain View, California, United States Palo Alto Medical Foundation, Mountain View, California, United States Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States UC Davis Health Investigational Drug Pharmacy, Sacramento, California, United States UC Davis Medical Center, Sacramento, California, United States Massachusetts General Hospital Translational and Clinical Research Center, Boston, Massachusetts, United States Massachusetts General Hospital, Clinical Trials Pharmacy, Boston, Massachusetts, United States Massachusetts General Hospital, Boston, Massachusetts, United States Regional One Health, Memphis, Tennessee, United States University Hospital Brugmann, Brussels, Belgium Santa Casa De Misericordia de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain Hospital Universitario Virgen Del Rocio, Sevilla, Spain |
| 1362 | Recruiting | Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER) | Immune Thrombocytopenia | Drug: Eltrombopag Drug: rhTPO |
Phase 1 | Peking University People's Hospital | OTHER | 30 | All | 18 Years ~ 80 Years | Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China |
| 1361 | Recruiting | FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals | COVID-19 | Drug: Favipiravir Drug: Lopinavir/ Ritonavir Other: Favipiravir Placebo Other: Lopinavir/ Ritonavir Placebo |
Phase 2 | University College, London, LifeArc | OTHER | 240 | All | 18 Years ~ 70 Years | Royal Free Hospital, London, United Kingdom University College London Hospital (UCLH), London, United Kingdom |